Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volagidemab Glucagon Rescue in T1D
NCT06272695Phase 1Completed
- Sponsor
- REMD Biotherapeutics, Inc.
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volagidemab in type 1 diabetes mellitus (T1D), sponsored by REMD Biotherapeutics, Inc. Primary endpoint: Change in Time to glucagon treatment success at 6 weeks. Started Feb 2024; status: completed.
02
Drugs
volagidemab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06272695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06272695.